MedTrace Logo

Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)

NCT01224626 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 41

Last updated 2012-07-02

Study results available
· View outcomes & findings →

Summary

To collect the efficacy and safety information in subjects who have been treated with Zyvox (linezolid) for vancomycin resistance Enterococcus faecium infection for their appropriate use in daily practice.

Conditions

  • Vancomycin Resistance Enterococcus Faecium

Interventions

DRUG

Zyvox (linezolid)

Patients should be treated with Zyvox (linezolid) 600 mg every twelve hours.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2011-04-30
Completion
2011-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01224626 on ClinicalTrials.gov